FindTrial
Sign In

How tests like p16, Ki-67, and HPV help doctors to detect and understand early cell changes in the cervix that could lead to cancer.

Role Of p16 and Ki-67 Immunocytochemistry along with HPV testing in Cervical Epithelial Abnormalities - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/099951
Enrollment
30
Registered
2025-12-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N879- Dysplasia of cervix uteri, unspecified Health Condition 3: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed cases of cervical epithelial abnormalities.

Exclusion criteria

Exclusion criteria: Cases of cervical infections and inflammatory lesions.Recurrent cases of cervical epithelial abnormalities.Age less than 21 years.

Design outcomes

Primary

MeasureTime frame
The main goal is to find out how accurately p16 Ki-67 and HPV testing can help detect and confirm early changes or abnormal changes of cancer of cervix when compared to standard histopathological examinationTimepoint: Baseline—

Secondary

MeasureTime frame
p16 and Ki-67 expression and HPV testing in different categories of cervical epithelial abnormalities as per The Bethseda System.Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Nidhi Verma

Maulana Azad Medical College

drnidhikamal@gmail.com8527271104

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026